With DMD, the progressive breakdown of skeletal muscle cells releases intracellular creatine kinase (mostly the muscle specific isoform CK-MM) into the circulation. Thereby the level of this biomarker in the blood can be used for the early detection of the disorder. PerkinElmer’s new GSP® Neonatal Creatine Kinase –MM (CK-MM) kit is a specific immunoassay for measuring CK-MM in newborn babies’ dried blood spot samples.
Recent therapeutic developments for DMD, along with new evidence of the importance of early intervention, has underscored the need for newborn screening of DMD. The new assay kit can dramatically improve efficiencies in newborn screening, providing children with opportunities for improved health.
In this webinar Dr. Stuart Moat from the University Hospital of Wales shares his experience of DMD screening and the assay performance